Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 6/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4921776 | 1.00 | TSHR (0.46) | TSHRALOX15ATMRORCGPR119 | |
| SCHEMBL655055 | 0.89 | MEN1 (0.45) | KDM1AKDM4E | |
| SCHEMBL4916837 | 0.89 | RORC (0.44) | RORCGPR119JAK2JAK1 | |
| SCHEMBL4924425 | 0.89 | RORC (0.44) | RORCGPR119JAK2JAK1 | |
| SCHEMBL14028090 | 0.87 | TACR1 (0.46) | TSHRALOX15ATMRORCGPR119 | |
| SCHEMBL14028091 | 0.87 | TSHR (0.47) | TSHRALOX15ATMRORCGPR119 | |
| SCHEMBL4601641 | 0.85 | NPSR1 (0.44) | OPRD1OPRK1 | |
| SCHEMBL4601058 | 0.85 | NPSR1 (0.44) | OPRD1OPRK1 | |
| SCHEMBL4911230 | 0.85 | TSHR (0.47) | TSHRALOX15ATMRORCGPR119 | |
| SCHEMBL4922956 | 0.80 | MC4R (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269233-A1 | Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds | ANDREWS MARK DAVID | 2008-10-30 | — | — | US | disclosed |
| US-20080269233-A1 | Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds | ANDREWS MARK DAVID | 2008-10-30 | — | — | US | disclosed |
| US-20080234280-A1 | Use of Mc4 Receptor Agonist Compounds | MCMURRAY GORDON | 2008-09-25 | — | — | US | disclosed |
| US-20080234280-A1 | Use of Mc4 Receptor Agonist Compounds | MCMURRAY GORDON | 2008-09-25 | — | — | US | disclosed |
| US-20080234280-A1 | Use of Mc4 Receptor Agonist Compounds | MCMURRAY GORDON | 2008-09-25 | — | — | US | disclosed |
| WO-2007015157-A2 | MC4R-AG0NISTS FOR THE TREATMENT OF URINARY TRACT DYSFUNCTION | PFIZER LIMITED (GB) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007015162-A1 | PIPERIDINOYL-PYRROLIDINE AND PIPERIDINOYL-PIPERIDINE COMPOUNDS | PFIZER LIMITED (GB) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269233-A1 | Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds | GPR4, GPR119, PRLHR | TSHR 1202/4885ALOX15 4629/4885ATM 2283/4885 |
| US-20080234280-A1 | Use of Mc4 Receptor Agonist Compounds | MC4R, MC5R, GPR4 | TSHR 347/4885ALOX15 970/4885ATM 3901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.